CA2220123A1 - Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine - Google Patents

Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine Download PDF

Info

Publication number
CA2220123A1
CA2220123A1 CA002220123A CA2220123A CA2220123A1 CA 2220123 A1 CA2220123 A1 CA 2220123A1 CA 002220123 A CA002220123 A CA 002220123A CA 2220123 A CA2220123 A CA 2220123A CA 2220123 A1 CA2220123 A1 CA 2220123A1
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
cells
polypeptides
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002220123A
Other languages
English (en)
Inventor
Craig A. Rosen
Steven M. Ruben
Haodong Li
Mark D. Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Human Genome Sciences Inc
Institute for Genomic Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Institute for Genomic Research filed Critical Human Genome Sciences Inc
Publication of CA2220123A1 publication Critical patent/CA2220123A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur la chimiokine bêta-8, la chimiokine bêta-1, la protéine 4 inflammatoire des macrophages, et de l'ADN (ARN) d'origine humaine codant pour ces polypeptides de chimiokine ainsi que sur une procédure permettant de fabriquer ces polypeptides par des techniques de recombinaison. L'invention se rapporte également à des procédés permettant d'utiliser ces polypeptides de chimiokine pour le traitement de la leucémie, des tumeurs, des infections chroniques, des maladies auto-immunes, des pathologies fibreuses, de la cicatrisation des plaies et du psoriasis. Elle concerne également des antagonistes agissant contre ces polypeptides de chimiokine et leur emploi en tant qu'agents thérapeutiques permettant de traiter la polyarthrite rhumatoïde, les maladies inflammatoires et infectieuses auto-immunes, chroniques et aigües, les réactions allergiques, la fièvre non dépendante de la prostaglandine et l'insuffisance médullaire. L'invention décrit également des méthodes de dosage diagnostique permettant de détecter des maladies se rapportant à des mutations dans les séquences d'acide nucléique et de déceler des concentrations de polypeptides modifiées.
CA002220123A 1995-05-05 1995-06-23 Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine Abandoned CA2220123A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44688195A 1995-05-05 1995-05-05
US08/446,881 1995-05-05

Publications (1)

Publication Number Publication Date
CA2220123A1 true CA2220123A1 (fr) 1996-11-07

Family

ID=23774170

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002220123A Abandoned CA2220123A1 (fr) 1995-05-05 1995-06-23 Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine

Country Status (8)

Country Link
EP (1) EP0871672A4 (fr)
JP (2) JPH11505417A (fr)
KR (1) KR19990008335A (fr)
CN (2) CN1515672A (fr)
AU (1) AU3134695A (fr)
CA (1) CA2220123A1 (fr)
MX (1) MX9708537A (fr)
WO (1) WO1996034891A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
EA199800352A1 (ru) * 1995-09-29 1998-12-24 Смитклайн Бичам Корпорейшн ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP0907736B1 (fr) * 1996-04-30 2006-02-01 Pharis Biotec GmbH Chemokines de type cc
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
KR20030097607A (ko) * 1996-09-30 2003-12-31 휴먼 게놈 사이언시즈, 인코포레이티드 골수양 선조 세포 억제 인자-1(ｍｐｉｆ-1)를 이용하여질병 상태를 치료하기 위한 치료 조성물 및 치료 방법
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
JP2002512521A (ja) 1997-05-30 2002-04-23 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ３２個のヒト分泌タンパク質
AU753157B2 (en) 1997-11-03 2002-10-10 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU4818599A (en) * 1998-07-06 2000-01-24 Schering Corporation Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods
EP0974357A1 (fr) 1998-07-16 2000-01-26 Schering-Plough Chemokines comme adjuvants de la réponse immunitaire
AU1716300A (en) 1998-11-10 2000-05-29 Beatson Institute For Cancer Research Chemokine beta-7
MXPA02003801A (es) * 1999-10-14 2002-10-23 Human Genome Sciences Inc Metodos para tratar o prevenir dano en celulas, tejidos y organos utilizando el factor inhibitorio progenitor de miloide-1 (mpfi-1) humano.
ES2272329T3 (es) * 1999-10-25 2007-05-01 Pharis Biotec Gmbh Quimioquinina humana phc-1 procesada.
EP1167527A1 (fr) * 2000-06-22 2002-01-02 Euroscreen S.A. Chemokines humaines tronquées: PHC-1 et PHC-2
EP2206720A1 (fr) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Protéines de fusion d'albumine
CA2413160A1 (fr) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Facteur de necrose tumorale humain delta et epsilon
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
WO2002000939A2 (fr) 2000-06-28 2002-01-03 Diadexus, Inc. Procede de diagnostic, de surveillance, de determination du stade, d'imagerie et de traitement du cancer du colon
EP1349946B1 (fr) 2000-08-25 2011-01-26 BASF Plant Science GmbH Polynucleotides vegetaux codant de nouvelles proteases prenyle
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
DE602004021419D1 (de) * 2003-12-05 2009-07-16 Oxagen Ltd Die aktivität von ccrl2 modulierende mittel und verfahren zu deren anwendung
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド アルブミン−インスリン融合タンパク質
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81168A0 (en) * 1986-01-08 1987-08-31 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene,its use,and cells containing the same
CA2091266A1 (fr) * 1990-09-14 1992-03-15 Patricia Tekamp-Olson Expression de proteines macrophages inductibles dans des cellules de levure
ATE262914T1 (de) * 1993-12-22 2004-04-15 Human Genome Sciences Inc Entzündungsproteine aus makrophagen mip-3, mip-4 und mip-1gamma
DE59410132D1 (de) * 1993-12-24 2002-07-11 Forssmann Wolf Georg Humanes zirkulierendes cytokin cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US5874211A (en) * 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils

Also Published As

Publication number Publication date
EP0871672A1 (fr) 1998-10-21
MX9708537A (es) 1998-02-28
CN1125082C (zh) 2003-10-22
AU3134695A (en) 1996-11-21
CN1515672A (zh) 2004-07-28
KR19990008335A (ko) 1999-01-25
WO1996034891A1 (fr) 1996-11-07
JPH11505417A (ja) 1999-05-21
EP0871672A4 (fr) 1999-05-12
CN1186501A (zh) 1998-07-01
JP2003102486A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
CA2220123A1 (fr) Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine
EP0792278B1 (fr) Polypeptide gamma appartenant a la famille des facteurs de necrose tumorale (fnt)
US6790826B2 (en) Human haemopoietic maturation factor
EP0735818B1 (fr) PROTEINES INFLAMMATOIRES MACROPHAGES MIP-3, MIP-4 ET MIP-1gamma
US6458349B1 (en) Chemokine β-4 polypeptides
AU723891B2 (en) Human chemokine beta-11 and human chemokine alpha-1
US6867006B2 (en) Antibodies to human chemotactic protein
EP0832233B1 (fr) Chemokine beta-13 humaine
AU708558B2 (en) Human chemokine beta-9
WO1996039421A1 (fr) Facteur de croissance 3 de l'endothelium vasculaire humain
WO1996024668A1 (fr) Chemokine humaine beta-11 et chemokine humaine alpha-1
US5880263A (en) Human chemotactic protein
WO1996039520A1 (fr) Chemokine beta-12 humaine
WO1996040762A9 (fr) Proteine-4 chimiotactique de monocyte
US20040126371A9 (en) Immune cell cytokine
AU753730B2 (en) Human chemokine beta-13
AU716100B2 (en) Human vascular endothelial growth factor 3
AU750982B2 (en) Human chemokine beta-11 and human chemokine alpha-1
US7393943B1 (en) Polynucleotides encoding a human chemotactic cytokine I
US20020119528A1 (en) Chemotactic cytokine III
CA2210471A1 (fr) Chemokine humaine beta-11 et chemokine humaine alpha-1
WO1997023640A1 (fr) Cytokine i chimiotactique de l'homme
CA2217216A1 (fr) Chemokine beta-13 humaine
AU2780600A (en) Human vascular endothelial growth factor 3

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued